N-Cyclopropyl-1-[3-(1-Oxidopyridin-3-yl)Phenyl]-1,4-Dihydro[1,8]Naphthyridin-4-One-3-Carboxamide | 477252-50-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-Cyclopropyl-1-[3-(1-Oxidopyridin-3-yl)Phenyl]-1,4-Dihydro[1,8]Naphthyridin-4-One-3-Carboxamide
• 英文别名: N-cyclopropyl-1-[3-(1-oxidopyridin-1-ium-3-yl)phenyl]-4-oxo-1,8-naphthyridine-3-carboxamide
• CAS: 477252-50-9
• 化学式: C₂₃H₁₈N₄O₃
• 分子量: 398.421
• InChiKey: AKWVYLGAPNUWLP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  87.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-cyclopropyl-1-[3-(pyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide 生成 N-Cyclopropyl-1-[3-(1-Oxidopyridin-3-yl)Phenyl]-1,4-Dihydro[1,8]Naphthyridin-4-One-3-Carboxamide
  参考文献：
  名称：

  1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors

  摘要：

  由化学式（I）表示的化合物： 1 或其药用可接受的盐，是磷酸二酯酶4抑制剂，用于治疗哮喘和炎症。

  公开号：

  US20030096829A1

文献信息

• Method of preparing inhibitors of phosphodiesterase-4
  申请人：——

  公开号：US20040102472A1

  公开（公告）日：2004-05-27

  In one aspect, the present invention is directed to a one pot method of preparing intermediates of Formula V, which are useful in making inhibitors of phosphodiesterase-4: 1 The present invention is also directed to a method of preparing phosphodiesterase inhibitors comprising the Formula 2

  在一个方面，本发明涉及一种制备Formula V中间体的一锅法，该中间体在制备磷酸二酯酶-4抑制剂时非常有用： 另外，本发明还涉及一种制备磷酸二酯酶抑制剂的方法，包括Formula 2。
• [EN] NOVEL CRYSTALLINE SALTS OF MONTELUKAST<br/>[FR] NOUVEAUX SELS CRISTALLINS DE MONTÉLUKAST
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2009052625A1

  公开（公告）日：2009-04-30

  The present application relates to crystalline 1,2-ethanedisulfonic acid salt and N,N'-dibenzylethylenediamine salt of montelukast. The salts are useful as therapeutic agents for the treatment of leukotriene mediated diseases and disorders. This application also relates to processes and intermediates for preparing the said salts and pharmaceutical compositions comprising the salts and optionally other therapeutic agents.

  本申请涉及蒙特卢卡斯特的结晶1,2-乙二磺酸盐和N,N'-二苯甲基乙二胺盐。这些盐在治疗白三烯介导的疾病和障碍方面是有用的治疗剂。本申请还涉及制备上述盐和制药组合物的过程和中间体，其中包括这些盐和可选的其他治疗剂。
• Use of phosphodiesterase-4 inhibitors as enhancers of cognition
  申请人：Dube Daniel

  公开号：US20060040981A1

  公开（公告）日：2006-02-23

  The present invention is directed to a method of enhancing cognition in a healthy subject comprising administering a safe cognition enhancing amount of a phosphodiesterase-4 inhibitor. In particular, this invention is directed to a method of enhancing memory, learning, retention, recall, awareness and judgement in health subjects comprising administering a safe and effective amount of a phosphodiesterase-4 inhibitor.

  本发明涉及一种增强健康受试者认知能力的方法，包括给予安全的磷酸二酯酶-4抑制剂增强认知能力的剂量。特别地，本发明涉及一种增强健康受试者记忆、学习、保留、回忆、意识和判断力的方法，包括给予安全有效的磷酸二酯酶-4抑制剂的剂量。
• Method of preparing inhibitors phosphodiesterase-4
  申请人：Albaneze-Walker Jennifer

  公开号：US20060019981A1

  公开（公告）日：2006-01-26

  In one aspect, the present invention is directed to a one pot method of preparing intermediates of Formula (V), which are useful in making inhibitors of phosphodiesterase-4: The present invention is also directed to a method of preparing phosphodiesterase inhibitors comprising the Formula (IX, IXa)

  在某个方面，本发明涉及一种制备公式（V）中间体的一锅法，该中间体在制备磷酸二酯酶-4抑制剂时非常有用：本发明还涉及一种制备公式（IX，IXa）的磷酸二酯酶抑制剂的方法。
• 1-BIARYL-1,8-NAPTHYRIDIN-4-ONE PHOSPHODIESTERASE-4 INHIBITORS
  申请人：Merck Frosst Canada & Co.

  公开号：EP1397359B1

  公开（公告）日：2005-08-31